Arrhythmia monitoring after cryptogenic stroke: choosing a device

Cardiac rhythm monitoring after cryptogenic stroke is not a single-test decision. An initial evaluation may label an ischaemic event as cryptogenic or, once major arterial and cardiac causes are excluded, as embolic stroke of undetermined source. An intermittent arrhythmia can still be responsible. Detecting paroxysmal atrial fibrillation may move a patient from antiplatelet therapy to anticoagulation, making rhythm surveillance part of stroke prevention.

No technology suits every patient. A 24-hour Holter, adhesive ECG patch, external event recorder, implantable loop recorder and smartphone or smartwatch answer different questions. Choice depends on stroke mechanism, symptom pattern, monitoring duration, feasibility and patient preference. In Australia, public and private diagnostic services, Medicare rebates, telehealth and direct-to-consumer devices all influence what can be arranged.

Why hidden atrial fibrillation matters

Cryptogenic stroke describes uncertainty rather than a proven mechanism. When imaging excludes a relevant arterial lesion and the initial cardiac assessment reveals no major embolic source, clinicians often use the term embolic stroke of undetermined source. This group can include patent foramen ovale, occult myocardial abnormalities and intermittent atrial fibrillation. Rhythm surveillance therefore complements detailed cardiac and vascular evaluation.

Intermittent AF is the principal target. Trials of implantable cardiac monitors in ESUS have detected newly recognised AF in approximately 8–12% of patients over about 12–18 months, compared with around 1–2% in conventional follow-up cohorts. A confirmed episode can affect anticoagulant selection, but duration, burden, comorbidity and bleeding risk need individual review. Brief device-detected AF is not automatically equivalent to sustained AF.

Timing matters because early AF may influence treatment differently from AF found many months later. Monitoring should begin promptly and continue beyond a single discharge period, with enough duration to capture asymptomatic episodes. The goal is trustworthy evidence at a clinically useful point, not the largest possible dataset. Original studies and reviews in the journal’s current articles provide a starting point for evaluating that evidence.

Holter monitoring: a short, focused snapshot

An external Holter ECG continuously records the heart, usually for 24 or 48 hours; some services offer up to seven days. It captures every beat during wear, supporting symptom-rhythm correlation and identifying ectopy, pauses or tachyarrhythmias. Familiarity, established workflows and Medicare rebates for medically indicated ambulatory ECG make it an accessible first extended test in many Australian settings.

Holter remains useful when symptoms are frequent, an inpatient assessment was inconclusive, or baseline information will guide further management. It can also document palpitations, dizziness and pauses. A patient-activated external loop recorder can bridge prolonged testing for infrequent symptoms, but it captures events only when activated. For a stroke with another clear arrhythmic explanation, its purpose differs from searching for hidden AF.

The central limitation is time. A normal 48-hour recording cannot exclude paroxysmal AF on day 60, and a study performed weeks after the stroke may miss a high-yield period. Holter should therefore be presented as a snapshot, not a rule-out test. A reassuring result should not automatically end the arrhythmic evaluation.

Patch monitoring: extending observation

An adhesive patch ECG monitor is worn on the chest, commonly for 14 days, and analyses rhythm while storing episodes for later download. Extended wear gives it more opportunity to detect AF than a 48-hour Holter and can capture asymptomatic events without daily button presses. Most patches use automated detection, sometimes alongside symptom-triggered recording.

After stroke, a patch can bridge inpatient telemetry and longer-term follow-up when an early arrhythmic mechanism is suspected. It is less disruptive than some alternatives and usually easier to arrange than an implant. Continuous data may also clarify AF burden, helping clinicians distinguish repeated short episodes from infrequent, longer episodes.

Two weeks still leaves most of the first year unobserved. Skin irritation, adhesive intolerance and the need for a clinic or remote download can affect suitability. Patch monitoring is strongest as a defined early-detection strategy, rather than a substitute for an implantable monitor when ESUS remains the working diagnosis.

Implantable loop recorders: surveillance over years

An implantable loop recorder, also called an implantable cardiac monitor, is placed under the skin of the chest. It continuously senses ECG and stores automatically triggered or patient-activated events for remote review. Depending on the model and battery, monitoring can continue for several years. Its main advantage is sustained surveillance without adhesive sensors or daily device handling.

For ESUS, an implantable monitor usually offers the highest yield among these options. It can capture asymptomatic paroxysmal AF, quantify episode burden and relate episodes to symptoms over a timeframe short external monitors cannot match. The findings can inform anticoagulation decisions, but detection does not prove that AF caused the stroke, and other embolic causes still require evaluation.

Trade-offs include a minor insertion procedure, wound care and rare complications such as infection or pocket haematoma. Patients need reliable follow-up and a plan for every detected episode. Medicare does not automatically fund every implantable indication, so referral criteria, device eligibility and local funding should be checked before implantation.

Mobile devices: useful adjuncts, not replacements

Mobile devices bring ECG or photoplethysmography-based rhythm assessment to the bedside. In Australia, smartphone ECG accessories and smartwatches are sold through pharmacies, electronics retailers and online marketplaces. A patient with palpitations can record a single-lead ECG at home for clinical review. Some watches also use pulse-wave signals to flag a possible arrhythmia.

These tools are strongest for a symptom-linked recording reviewed by a clinician. They are weaker for silent surveillance: motion, poor skin contact, ectopy and atrial flutter can trigger AF alerts, while a normal wrist reading cannot exclude AF. A wearable usually cannot measure AF burden, replace a 12-lead ECG or match the diagnostic assurance of prolonged physician-prescribed monitoring. Consumer notifications are prompts for assessment, not definitive diagnoses.

Mobile devices can fill a practical gap by documenting an episode sooner than a waiting-list patch or helping a clinician judge whether symptoms are arrhythmic. For broader device and electrophysiology context, the journal’s themed collections can be useful alongside local protocols. These products should complement formal stroke investigation, not delay it or replace indicated anticoagulation assessment.

Matching monitoring to the Australian stroke pathway

In cities such as Melbourne, Sydney, Brisbane and Perth, stroke units and cardiology services can usually access telemetry, external event recorders and implantable monitoring through hospital or private pathways. Medicare can rebate medically prescribed ambulatory ECG, while coverage for long-term implants varies with eligibility and the service model. Selection should follow current Australian stroke and arrhythmia guidance, including National Heart Foundation recommendations.

Access is not uniform. For people in regional, rural and remote northern Australia, follow-up may depend on telehealth, remote interrogation, nurse-led reviews and outreach from tertiary centres. A monitor checked from a regional hospital or home can reduce travel. The plan should also account for patient education, language, connectivity and a clearly identified clinician who will act on results.

A practical sequence is inpatient surveillance and early ambulatory ECG, followed by a patch for a defined two-week window or an implantable monitor for prolonged ESUS evaluation. A mobile ECG can support symptom assessment between appointments. Local policy should specify who reviews results and when anticoagulation is reconsidered. For conditions attached to online access, the journal’s site terms should be checked separately from clinical guidance.

Turning the comparison into an actionable plan

Before discharge, record the suspected stroke mechanism, the reason for monitoring, its planned duration and the clinician responsible for follow-up. Give patients plain-language instructions on marking symptoms, operating an external device and seeking urgent help for new neurological symptoms. If AF is detected, document episode duration, burden, symptoms and the anticoagulation assessment rather than treating the notification as the final decision.

At reassessment, match the next device to the unresolved question: a Holter or patch for a focused early window, an implantable loop recorder for sustained surveillance, or mobile ECG for symptom clarification alongside formal follow-up. Review the actual recordings, symptom diary and current Australian guidance together, rather than choosing by device availability alone.

Make the next step an arranged action: schedule the review date, confirm access to the chosen service and ensure every detected episode has a predefined clinical response. Complete the monitoring plan before discharge, so surveillance leads to a documented decision about anticoagulation and further stroke prevention.